letrozole (Femara)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Femara.

Indications

Dosage

Pharmacokinetics

Adverse effects

* consider concurrent Ca+2, vitamin D & bisphosphonate treatment

Mechanism of action

More general terms

Additional terms

Component of

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, Update 9/99
  2. Prescriber's Letter 8(2):10 2001
  3. Prescriber's Letter 10(11):64 2003
  4. 4.0 4.1 4.2 Journal Watch 23(22):173, 2003 Goss PE et al, N Engl J Med 349:1793, 2003 http://content.nejm.org/cgi/reprint/NEJMoa032312v1.pdf PMID: https://www.ncbi.nlm.nih.gov/pubmed/14551341 Bryant J & Wolmark N, N Engl J Med 349:1855, 2003 Burnstein HJ, N Engl J Med 349:1857, 2003
  5. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine- responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17200148
  6. 6.0 6.1 Deprecated Reference
  7. 7.0 7.1 Legro RS et al Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. N Engl J Med 2014; 371:119-129. July 10, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25006718 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1313517
  8. 8.0 8.1 Colleoni M, Luo W, Karlsson P et al Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology. Nov 17, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29158011 <Internet> http://thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30715-5/fulltext
    Chlebowski RT, Pan K. Complexity of intermittent letrozole adjuvant therapy. The Lancet Oncology. Nov 17, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29158010 <Internet> http://thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30854-9/fulltext

Database